A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer

Table 1 Patient demographics

	Fulvestrant 500 mg	Fulvestrant 500 mg + anastrozole 1 mg	Anastrozole 1 mg
n	35	31	37
Age, years
Mean	67.9	64.2	64.8
Standard deviation	8.5	10.2	8.7
Tumor grade^a
1	8	9	8
2	23	16	25
3	4	4	4

^aTwo patients in the fulvestrant 500 mg plus anastrozole group had bilateral breast tumors of differing grades and are not included in the above baseline grade table.

ISSN: 1465-542X